The prototypic cannabinoid type 1 (CB 1 ) receptor antagonist/inverse agonist, rimonabant, is comprised of a pyrazole core surrounded by a carboxyamide with terminal piperidine group (3-substituent), a 2,4-dichlorophenyl group (1-substituent), a 4-chlorophenyl group (5-substituent), and a methyl group (4-substituent). Previous structureactivity relationship (SAR) analysis has suggested that the 3-position may be involved in receptor recognition and agonist activity. The goal of the present study was to develop CB 1 -selective compounds and explore further the SAR of 3-substitution on the rimonabant template. 3-Substituted analogs with benzyl and alkyl amino, dihydrooxazole, and oxazole moieties were synthesized and evaluated in vitro and in vivo. Several notable patterns emerged. First, most of the analogs exhibited CB 1 selectivity, with many lacking affinity for the CB 2 receptor. Affinity tended to be better when [ Several analogs were inverse agonists in the latter assay. Together, these results suggest that this series of 3-substituted pyrazole analogs represent a novel class of CB 1 -selective cannabinoids that produce agonist-like effects in mice through a non-CB 1 , non-CB 2 mechanism.
Introduction
Rimonabant, formerly known as SR141716 [(Ϫ)-cis-3-[2-hydroxy-4(1,1-dimethyl-heptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol], is the prototypic antagonist of cannabinoid type 1 (CB 1 ) receptors (Rinaldi-Carmona et al., 1994) . Its discovery in 1994 intensified interest in scientific research on cannabinoids by providing a valuable pharmacological tool for investigating the structure of the CB 1 receptor and determining the role of this receptor within the (then) newly discovered endocannabinoid system (Devane et al., 1992) . Later research suggested that rimonabant may not be a neutral CB 1 antagonist, but rather may have inverse agonist effects (Landsman et al., 1997; Pan et al., 1998) . In vivo, rimonabant has been reported to antagonize various effects of cannabinoid agonists from several classes, including the tetrahydrocannabinols [e.g., ⌬ 9 -tetrahydrocannabinol (THC); Compton et al., 1996] , bicyclic cannabinoids [e.g., (Ϫ)-cis-3- [2-hydroxy-4(1,1-dimethyl-heptyl) phenyl]-trans-4-(3-hydroxy-propyl)cyclohexanol (CP55,940); Wiley et al., 1995a] , aminoalklyindoles [e.g., (R)-(ϩ)- [2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo [1,2,3-de] -1,4-benzoxazin-6-yl]-1-napthalenylmethanone (WIN55,212-2); Fattore et al., 2001 )], and anandamide-like cannabinoids (Murillo-Rodríguez et al., 2001) . When administered alone, rimonabant decreases feeding behavior (Wiley et al., 2005) , has discriminative stimulus effects (Järbe et al., 2004) , and stimulates locomotor activity , the last of which is not related to rimonabant interaction with the CB 1 receptor (Bass et al., 2002) . In humans, rimonabant was originally marketed as an antiobesity agent and an aid to smoking cessation until its adverse psychiatric effects were revealed during advanced clinical trials (Christensen et al., 2007) . Nevertheless, rimonabant remains an excellent template for the investigation of structural requirements for the recognition and activation of CB 1 receptors.
Previous structure-activity relationship (SAR) studies have examined rimonabant analogs that retain a central pyrazole structure with manipulation of one of four other areas of the molecule: 1) substitution for carboxyamide and/or piperidine substituent (3-substituent); 2) substitution for the 2,4-dichlorophenyl group (1-substituent); 3 substitution for chlorophenyl group (5-substituent); or 4) substitution for the methyl (4-substituent) ( Table 1) . Of these various substituents, the 1-substituent is the most unique and is hypothesized to be related to the antagonist properties of rimonabant (Thomas et al., 1998) , whereas the 3-substituent has been suggested to be involved in receptor recognition (Wiley et al., 2001 ) and its inverse agonist effects (Hurst et al., 2006) . In an earlier study (Wiley et al., 2001) , we reported that some 3-substituted rimonabant analogs possessed in vivo effects in mice that are characteristic of cannabinoid agonists and partial agonists, including suppression of locomotor activity, antinociception, hypothermia, and catalepsy (Martin et al., 1991) . Here, we evaluated further the structure-activity relationship of novel 3-substituent rimonabant analogs in vitro and in vivo, with the dual purpose of 1) development of better understanding of the influence of this part of the pyrazole template on CB 1 receptor affinity and functioning and 2) discovery of a CB 1 receptor-selective agonist. Whereas many traditional cannabinoid agonists such as THC, CP55,940, and WIN55,212-2 bind to both CB 1 and CB 2 receptors with good affinity, rimonabant shows good selectivity for the CB 1 (versus CB 2 ) receptor (Showalter et al., 1996) ; hence, our goal was to optimize CB 1 agonist activity by manipulating the 3-substituent while retaining the pyrazole core in an effort to maintain or improve selectivity. In this study, we have evaluated the in vitro and in vivo effects of structural modification at the 3-position of rimonabant analogs, with the purpose of understanding the role of this position in both agonism and receptor activation.
Materials and Methods

Subjects
Male ICR mice (25-32 g), obtained from Harlan (Dublin, VA) and housed in groups of five, were used for assessment of locomotor suppression, antinociception, hypothermia, and catalepsy. Separate mice (n ϭ 5-6 per dose/dose combination, unless otherwise indicated) were used for testing each dose of each compound in this battery of procedures. A subset of pyrazole analogs were also tested in vivo in male and female CB 1 knockout [CB 1 (Ϫ/Ϫ)] and wild-type [CB 1 (ϩ/ϩ)] mice, bred on a C57BL/6 background, as described previously (Zimmer et al., 1999) . These mice were derived from breeding pairs of heterozygotes (obtained from A. Zimmer, National Institute of Mental Health, Bethesda, MD) and born at Virginia Commonwealth University. Because of limited supply, the transgenic mice were tested with more than one compound or dose of compound. All mice had free access to food in their home cages and were kept in a temperature-controlled (20 -22°C) environment with a 12-h light/ dark cycle (lights on at 7:00 AM). The in vivo studies reported here were carried out in accordance with guidelines published in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996) and approved by the Institutional Animal Care and Use Committee at Virginia Commonwealth University.
Apparatus
Measurement of spontaneous activity in mice occurred in standard activity chambers interfaced with a Digiscan Animal Activity Monitor (Omnitech Electronics, Inc., Columbus, OH). A standard tailflick apparatus and a digital thermometer (Thermo Fisher Scientific, Waltham, MA) were used to measure antinociception and rectal temperature, respectively.
Drugs
Pyrazole analogs (synthesized in the laboratory at Organix, Inc.), THC (National Institute on Drug Abuse, Bethesda, MD), and rimonabant (National Institute on Drug Abuse) were mixed in a vehicle of ethanol, Emulphor (Rhone-Poulenc, Inc., Princeton, NJ), and saline in a 1:1:18 ratio. All injections were administered intravenously at a volume of 0.1 ml/10 kg.
Procedures
Membrane Preparations. Chinese hamster ovary cells stably expressing the human CB 1 or CB 2 receptor were cultured in a 50:50 mixture of Dulbecco's modified Eagle's medium and Ham F-12 supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, 0.25 mg/ml G418, and 5% fetal calf serum. Cells were harvested by replacement of the media with cold phosphate-buffered saline containing 0.4% EDTA followed by agitation. Membranes were prepared by homogenization of cells in 50 mM Tris-HCl, 3 mM MgCl 2 , and 1 mM EGTA, pH 7.4, centrifugation at 50,000g for 10 min at 4°C, and resuspension in the same buffer at 1.5 mg/ml. Membranes were stored at Ϫ80°C until use.
Radioligand Binding. Membranes were diluted with assay buffer B (50 mM Tris-HCl, pH 7.4, 3 mM MgCl 2 , and 0.2 mM EGTA). Reactions containing membrane (10 g of protein) were incubated with 0.5 nM [
3 H]SR141716 (CB 1 ) or 1 nM [ 3 H]CP55,940 (CB 1 or CB 2 ) and varying concentrations of test compounds in assay buffer B containing 0.5% BSA. Nonspecific binding was measured in the presence and absence of 5 M unlabeled SR141716 (CB 1 ) or 10 M unlabeled WIN 55,212-2 (CB 2 ). The assay was incubated for 60 min at 30°C and terminated by rapid filtration under vacuum through Whatman (Clifton, NJ) GF/B glass fiber filters that were presoaked in Tris buffer containing 5 g/liter BSA (Tris-BSA), followed by five washes with cold Tris-BSA. Bound radioactivity was determined by liquid scintillation spectrophotometry at 45% efficiency for 3 H. [ 35 S]GTP␥S Binding. Before assays, samples were thawed on ice, centrifuged at 50,000g for 10 min at 4°C, and resuspended in assay buffer A (50 mM Tris-HCl, pH 7.4, 3 mM MgCl 2 , 0.2 mM EGTA, and 100 mM NaCl). Reactions containing 10 g of membrane protein were incubated for 90 min at 30°C in assay buffer A containing 10 M GDP, 0.1 nM [
35 S]GTP␥S, 0.1% bovine serum albumin, and various concentrations of test compounds. Nonspecific binding was determined in the presence of 20 M unlabeled GTP␥S. Reactions were terminated by rapid vacuum filtration through GF/B glass Showalter et al. (1996) . d Data from Wiley et al. (1998) .
fiber filters, and radioactivity was measured by liquid scintillation spectrophotometry at 95% efficiency for 35 S. Tetrad Tests in Mice. Each mouse was tested in a battery of four tests, in which cannabinoid agonists produced a characteristic profile of in vivo effects (Martin et al., 1991) : suppression of locomotor activity, antinociception in the tail-flick assay, decreased rectal temperature, and ring immobility. Before injection, rectal temperature and baseline latency in the tail-flick test were measured in the mice. The latter procedure involved exposing the mouse's tail to an ambient heat source (i.e., bright light) and recording latency (in seconds) for tail removal. Typical control latencies were 2 to 4 s. A 10-s maximal latency was used to avoid damage to the mouse's tail. After measurement of temperature and baseline tail-flick latency, mice were injected intravenously with vehicle or drug. Five minutes later they were placed into individual activity chambers for 10 min. Spontaneous activity was measured as the total number of beam interruptions during the entire session, which was expressed as the percentage of inhibition of the control (vehicle) group's activity. Tailflick latency was measured at 20 min after injection. Antinociception was expressed as the percentage of maximum possible effect (MPE) by using a 10-s maximum test latency. Rectal temperature was measured at 30 min after injection and expressed as the difference between preinjection and postinjection rectal temperatures. At 40 min after injection, the mice were placed on a 5.5-cm ring attached at a height of 16 cm to a ring stand, and the amount of time the animals remained motionless during a 5-min period was recorded. The time that each animal remained motionless on the ring was divided by 300 s and multiplied by 100 to obtain a percentage immobility rating. Whenever quantity of compound allowed, a full dose-effect curve determination in the tetrad tests was conducted; however, insufficient quantities of some of the compounds resulted in probe tests with a single dose.
Evaluation of antagonism of THC's effects in the tetrad was accomplished by intravenous injection of the 3-substituted pyrazole analog followed 10 min later by an intravenous injection of 3 mg/kg THC. Given that many of the compounds produced in vivo effects that were agonist-like and did not function as antagonists (against THC), rimonabant reversal of the in vivo effects of selected compounds was also assessed. For these tests, vehicle or rimonabant was injected intravenously 10 min before intravenous injection of the test compound. In both types of antagonist evaluations, in vivo tests were then conducted by using the same time course and procedure described above.
Selected pyrazole analogs were also evaluated in CB 1 (Ϫ/Ϫ) and CB 1 (ϩ/ϩ) mice in three in vivo assays: spontaneous activity, rectal temperature, and ring immobility. Because these mice were tested more than once, tail-flick assays were not performed to avoid repeated exposure of the tail to a painful stimulus. All other experimental parameters were identical as those described for the ICR mice.
Data Analysis. Rectal temperature values were expressed as the difference between control temperature (before injection) and temperatures after drug administration (⌬ o C). Spontaneous activity was measured as total number of photocell beam interruptions during the 5-min session and expressed as the percentage of inhibition of activity of the vehicle group. During assessment for catalepsy, the total amount of time (in seconds) that the mouse remained immobile on the ring apparatus was measured and used as an indication of catalepsy-like behavior. This value was divided by 300 s and multiplied by 100 to obtain a percentage of immobility. Data analysis was based on a scheme we have used in numerous previous studies with cannabinoids, with maximal cannabinoid effects in each procedure estimated as follows: 90% inhibition of spontaneous activity, 100% MPE in the tail-flick procedure, Ϫ6°C change in rectal temperature, and 60% ring immobility. ED 50 was defined as the dose at which half-maximal effect occurred. For compounds that produced one or more cannabinoid effects, ED 50 was calculated separately by using least-squares linear regression on the linear part of the dose-effect curve for each measure in the mouse tetrad, plotted against log10 transformation of the dose. Rimonabant reversibility of the pharma- -pyrazole-3-carboxamide (O-4332) and four other selected analogs in mice was analyzed with separate factorial (rimonabant treatment condition ϫ O-4332 dose or pyrazole analog, respectively) ANOVAs for each dependent measure. Separate factorial (genotype ϫ treatment compound) ANOVAs were also used to analyze the effects of selected compounds in CB 1 (Ϫ/Ϫ) and CB 1 (ϩ/ϩ) mice. Significant main effects and interactions were further analyzed with Tukey post hoc tests (␣ ϭ 0.05) as necessary.
For the CB 1 and CB 2 receptor binding experiments, displacement IC 50 values were originally determined by Hill plots and then converted to K i values by using the method of Cheng and Prusoff (1973) 
Results
To further explore the structure-activity relationship at the 3-position of rimonabant, several alkylamide analogs were synthesized with varying chain length and varying functional groups at the terminal end of the chain. Table 1 shows CB 1 and CB 2 receptor binding affinities and in vivo potencies of these rimonabant analogs. Assessment of control compounds showed that rimonabant had good affinity for the CB 1 receptor, regardless of which of the two radioligands was used for the displacement assay, albeit it displaced [ 3 H]SR141716 at 3-fold lower concentrations than it displaced [ 3 H]CP55,940. In contrast, THC and CP55,940 exhibited better affinity for the CB 1 receptor when tritiated agonist was used as a radioligand than when tritiated antagonist was used. Whereas THC also had good binding affinity at CB 2 receptors, rimonabant was relatively selective for CB 1 receptors, having poor affinity at CB 2 receptors. In vivo, rimonabant stimulated locomotor activity and was inactive in the other three tetrad tests. In contrast, THC produced cannabimimetic effects in all in vivo tests.
All of the 3-substituted analogs of rimonabant in Table 1 shared the property of CB 1 receptor selectivity. The best CB 2 receptor affinity (K i ) of 298 nM, which was observed with O-4372, was still only moderate, with CB 2 receptor affinities of the other compounds ranging from 555 to 3658 nM for O-4371 and O-4423, respectively. Furthermore, the analogs shared with rimonabant the property of better displacement of [
3 H]SR141716 versus [ 3 H]CP55,940, ranging from 1.6-to 4.7-fold when affinity was assessed with the former radioligand. Although none of the analogs had better CB 1 receptor affinity than rimonabant, the benzyl amide analogs (O-4333 and O-4334) resulted in reasonable CB 1 affinities, but were not active in vivo. In contrast, the alkylamide analogs (O-4331 and O-4332) showed substantially decreased CB 1 receptor affinities. We were surprised to find, however, that these compounds possessed cannabimimetic activity in the tetrad tests, with reasonable potencies (2.5-20 g/kg) that belied their relatively poor CB 1 receptor affinities.
For the bromo and cyano series (Table 1) , CB 1 receptor affinities improved as the carbon chain was lengthened, with best affinities (as measured by [ 3 H]SR141716 displacement) exhibited by compounds with a pentylbromo (O-4371) or pentylcyano (O-4372) substitution. At comparable carbon chain lengths from ethyl to pentyl, a terminal bromo group resulted in better CB 1 receptor affinity compared with a terminal cyano group. Addition of a terminal double bond (O-4373) or branching of the carbon chain (O-4423) did not notably improve CB 1 receptor affinity. Regardless of magnitude of CB 1 receptor affinity, however, all of these 3-substituent bromo and cyano side chain analogs were active in the in vivo tetrad tests. Potencies ranged from 5 to 28 g/kg, but did not necessarily correspond with CB 1 receptor affinities. For example, O-4337 had poor CB 1 receptor affinity (K i ϭ 420 nM; CP55,940 displacement); yet, it was active in all four tests at similar or lower potencies than O-4371, a compound with one of the best CB 1 receptor affinities (K i ϭ 39 nM; CP55,940 displacement). Table 2 shows CB 1 and CB 2 receptor binding data and in vivo potencies for 3-substituted pyrazole analogs in which the 3-amido moiety of rimonabant was replaced with dihydrooxazole moiety (O-4338), oxazole moiety (O-6668), or amino substituents (O-6729, O-6730, O-6731, and O-6740) . These compounds maintained the CB 1 receptor selectivity that was observed with previous compounds and had good to fair affinity for this receptor (range 45-290 nM; SR141716 displacement). For this series, CB 1 receptor binding affinities were more similar between the two radioligands used for the displacement assays, with ratios of [ Table 1 . In contrast, compounds that lacked an amide moiety or dihydrooxazole moiety (O-6740, O-6729, O-6730, and O-6731) were inactive in all in vivo assays at doses up to 30 mg/kg. Table 3 presents binding and in vivo results with 3-substituted pyrazole analogs in which the amide group of rimonabant was replaced with an isosteric dihydrooxazole moiety. The unsubstituted dihydrooxazole analog O-4338 (Table 2) showed the best selectivity for CB 1 receptors, having no measureable affinity for CB 2 receptors. Although selective, O-4338 nonetheless exhibited poor CB 1 receptor affinity (K i ϭ 680 nM; CP55,940 displacement). In an effort to retain selectivity while improving affinity, a number of alkyl ethersubstituted dihydrooxazole analogs were synthesized (Table  3) . Like O-4338, none of these ether analogs had measurable binding affinity at CB 2 receptors. Furthermore, CB 1 receptor affinity was enhanced in all of the compounds, 2-to 8-fold 3 H]CP55,940 was used. It is noteworthy that, with the exception of O-4424, all of these compounds were also active in the in vivo tetrad of tests. O-4424 could not be assessed because of insufficient quantities. When sufficient quantities allowed, a dose-effect curve was determined in vivo, with potencies ranging from 2 to 36 g/kg. (Fig. 1, bottom) .
Because the compounds presented in Tables 1 to 3 are analogs of the CB 1 receptor antagonist rimonabant, selected compounds provided in sufficient quantity were evaluated to determine reversal of the cannabimimetic effects of 3 mg/kg THC in the tetrad ( combination with vehicle or 10 mg/kg rimonabant on locomotor activity (top left), antinociception (top right), rectal temperature (bottom left), and ring immobility (bottom right). Factorial ANOVA revealed a significant main effect of the compounds for locomotor activity (F 4,82 ϭ 89.0; p Ͻ 0.05), with significant decreases compared with vehicle produced by each of the four compounds revealed by Tukey post hoc analysis. The pretreatment ϫ compound interaction was also significant (F 4,82 ϭ 3.1; p Ͻ 0.05), with post hoc analysis showing that the 10 mg/kg dose of rimonabant increased locomotion compared with vehicle treatment. For antinociception, significant main effects of pretreatment condition and compound were observed (F 1,86 ϭ 4.7; p Ͻ 0.05 and F 4,86 ϭ 263.6; p Ͻ 0.05, respectively). Post hoc analysis revealed that each of the four compounds produced antinociception compared with the groups that received vehicle or rimonabant, and rimonabant produced a significant, but small in magnitude, overall increase in antinociception. Similar significant main effects of pretreatment condition and compound were obtained for the rectal temperature measure (F 1,86 ϭ 7.6; p Ͻ 0.05 and F 4,86 ϭ 125.3; p Ͻ 0.05, respectively), with each compound producing a significant decrease in temperature (regardless of whether vehicle or rimonabant pretreatment occurred). Overall, rimonabant slightly, but significantly, increased the magnitude of this temperature decrease. For the ring immobility measure, a significant main effect of compound and a significant interaction were observed (F 1,72 ϭ 14.4; p Ͻ 0.05 and F 3,72 ϭ 10.6; p Ͻ 0.05, respectively). Three of the four compounds (O-6211, O-6629, and O-6668) significantly increased time spent immobile on the ring apparatus. For O-6211 and O-6629, immobility was increased further by pretreatment with rimonabant, whereas O-6668-induced immobility was decreased by rimonabant, although it was still significantly enhanced compared with vehicle. Data for O-6658 were unavailable for this measure, because the mice that received this compound could not maintain balance on the ring and fell off repeatedly. Figure 4 shows the effects of 30 mg/kg O-4332 and 10 mg/kg O-6629, O-6658, and O-6668 in CB 1 (Ϫ/Ϫ) and CB 1 (ϩ/ϩ) mice on locomotor activity (top), ring immobility (middle), and rectal temperature (bottom). All of the selected compounds suppressed locomotor activity, increased ring immobility, and decreased rectal temperature in both genotypes, as indicated by significant main effects with follow-up post hoc analysis for each measure (F 4,57 ϭ 75.3, p Ͻ 0.05; F 4,59 ϭ 77.5, p Ͻ 0.05; and F 4,54 ϭ 158.1, p Ͻ 0.05, respectively), with significant differences compared with vehicle produced by each of the four compounds that were revealed by Tukey post hoc analyses.
Discussion
Previous research has shown that manipulation of the 3-substituent of rimonabant results in orderly changes in CB 1 receptor recognition (Lan et al., 1999; Wiley et al., 2001; Francisco et al., 2002) , with some of the manipulations resulting in pharmacological activity in mice that was cannabinoid agonist-like (Wiley et al., 2001) . The results here seem to reinforce the hypothesis that the 3-substituent is involved in cannabimimetic activity, because many of these compounds showed good potency in decreasing locomotor activity and producing antinociception and hypothermia. Furthermore, they exhibited good CB 1 receptor selectivity, with some of the compounds having no measurable affinity for the CB 2 receptor. In particular, substitution of a dihydrooxazole moiety at the 3-position of the pyrazole core, with or without addition of a terminal ether alkyl group, eliminated CB 2 affinity, whereas most analogs in the series still retained good to moderate CB 1 affinity. Previous research has suggested that a structural feature of pyrazole analogs that enhances CB 1 binding affinity and is crucial to their inverse agonism is the carboxamide oxygen (Hurst et al., 2006) . The present results suggest that moderate CB 1 affinity and inverse agonism were retained by compounds with 3-substituted dihydrooxazole and oxazole moieties (see compounds in Tables 2 and 3 ), but lacking a carboxamide oxygen. These com- jpet.aspetjournals.org pounds also exhibited the greatest CB 1 receptor selectivity, suggesting that the carboxamide oxygen may play a role in residual CB 2 receptor affinity of rimonabant and its analogs that contain it (see Table 1 ). Nevertheless, compared with compounds possessing only nitrogen-containing substituents (e.g., O-6729, O-6731, and O-6740) , better CB 1 affinity was observed for compounds with a carboxamide substituent (e.g., O-4333 and O-4334) (Thomas et al., 1998 (Thomas et al., , 2005 Gullapalli et al., 2010) . The enhanced affinity shown here by the pyrazole analogs possessing agonist-like effects suggests that the basis for the differences in affinities resides in the structural (versus functional) properties of the compound. The compounds did not stimulate [
35 S]GTP␥S binding; however, antagonism in this assay was not evaluated.
Several aspects of the cannabinoid agonist-like activity of the 3-substituted pyrazole analogs in mice remain puzzling. First, potencies for producing cannabinoid agonist-like effects were not highly correlated with CB 1 receptor binding affinities. In contrast, investigations of the SARs of cannabinoid agonists based on the structural templates of THC and CP55,940 (Compton et al., 1993) or WIN55,212-2 (Wiley et al., 1998) typically report strong correlations between CB 1 receptor binding affinities and potencies for these measures in mice. A second inconsistency is the lack of stimulation of CB 1 receptors in [ 35 S]GTP␥S binding, a functional assay of activation of G protein-coupled receptors. All other classes of cannabinoid agonists produce this effect (Selley et al., 1996; Breivogel and Childers, 2000) , whereas rimonabant has been shown to be an inverse agonist in this assay (Landsman et al., 1997) . Indeed, several of the analogs presented here also exhibited inverse agonism, suggesting greater similarity to CB 1 receptor antagonists than agonists in vitro. In addition, structural variants of O-4333 and O-4334 with identical 3-substituents, but that also contained 4-cyanomethyl substitution on the pyrazole core, potently antagonized CP55,940-induced stimulation of [ 35 S]GTP␥S (Cooper et al., 2010) . O-4333 and O-4334 also partially blocked the effects of THC in vivo without having agonist activity when administered alone. Yet, with the exception of these two compounds and a couple of others (O-2155 and O-4336 ) that possessed remnants of antagonist activity in vivo, the selected compounds that were tested as antagonists did not block the in vivo agonist effects of THC, as previous reports have shown that rimonabant does (Rinaldi-Carmona et al., 1995; Compton et al., 1996) . The active 3-substituted pyrazoles presented here also are not likely to be producing their effects through activation of CB 2 receptors. Although research provides evidence of the possibility of CB 2 receptors in the brain (Van Sickle et al., 2005; Onaivi et al., 2006) , the localization and function of these receptors (e.g., neuronal versus glial) remain uncertain (Cabral et al., 2008) . In addition, challenge tests with the CB 2 receptor antagonist 5-(4-chloro-
1H-pyrazole-3-carboxamide (SR144528) have shown that this compound did not reverse the cannabimimetic effects of THC analogs in this battery of tests , suggesting that CB 2 receptors do not mediate the effects. Finally, the compounds with the most potency in vivo were CB 1 receptor selective, having very low or absent affinity for CB 2 receptors.
In an effort to determine whether the cannabinoid agonistlike action of these compounds might be produced by interaction with CB 1 receptors despite the contradictory results of the SAR analysis, the effects of rimonabant were evaluated in combination with O-4332, one of the compounds that was active in all tests. Although the binding affinity for CB 1 receptors was poor, it was comparable with that of JWH-104 (deoxy-⌬ 9(11) -THC-dimethylheptyl), a compound that was previously shown to have cannabimimetic effects in these tests through low efficacy activation of the CB 1 receptor . In the present study, the agonist effects of O-4332 were replicated; however, rimonabant failed to block O-4332-induced hypomobility and antinociception, suggesting that these effects were not CB 1 receptor-mediated. Rimonabant also did not reverse the in vivo effects of O-6211, O-6629, O-6658, and O-6668, each of which had much better CB 1 receptor selectivity and binding affinities than O-4332. A similar pattern of activity in all tests without rimonabant reversibility has been noted with antipsychotics (Wiley and Martin, 2003) , suggesting that activity in the test battery is selective, but not specific, for cannabinoids. Conceivably, then, the pyrazole analogs could be working via a noncannabinoid mechanism. Conversely, rimonabant readily blocks the effects of cannabinoid agonists. For example, it reversed the effects of the low-efficacy cannabinoid agonist JWH-104 and has been shown to block the in vivo effects of various classes of cannabinoid agonists in several species (Rinaldi-Carmona et al., 1994; Wiley et al., 1995b; Compton et al., 1996; Huestis et al., 2001) . Instances in which rimonabant did not reverse the effects of cannabinoids also have been reported, particularly for anandamide (Adams et al., 1998) ; however, the influence of differences in pharmacokinetic factors between THC-and anandamide-like cannabinoids cannot be ruled out. Likewise, pharmacokinetic factors may have also influenced the in vivo results obtained here and is one direction for future research.
In addition to the assessment of rimonabant reversal of their in vivo effects, selected pyrazoles were evaluated in CB 1 (Ϫ/Ϫ) and CB 1 (ϩ/ϩ) mice. The finding that these compounds produced cannabinoid agonist-like effects in both genotypes adds further support to the hypothesis that they are not producing their in vivo effects via activation of CB 1 receptors, despite the fact that some of them bind quite well to this receptor. Given these seemingly contradictory results, a crucial question is the mechanism through which these novel pyrazoles are producing their cannabinoid agonist-like in vivo effects. Although this mechanism may be noncannabinoid (as discussed in the preceding paragraph), the fact that the structure of the compounds closely resembles that of rimonabant, a known cannabinoid antagonist, combined with the finding that many of these compounds actually do bind to CB 1 receptors suggests that their effects reflect cannabinoid activity. Furthermore, it is conceivable that this activity may be mediated through a CB 3 receptor that has been hypothesized (for a review, see include deorphanized G protein-coupled receptors such as GPR55, transient receptor potential vanilloid 1 ion channels, or peroxisome proliferator-activated receptors (e.g., peroxisome proliferator-activated receptor ␥) (for a comprehensive review, see Pertwee et al., 2010) .
In summary, this study reports the discovery of a novel class of 3-substituted pyrazole analogs with good to moderate affinity for CB 1 receptors and without measurable affinity for CB 2 receptors. Although many of these compounds produced in vivo effects in mice that were similar to those observed with CB 1 agonists such as THC, the poor correlation between CB 1 binding affinity and potency in the tetrad tests suggests that these effects were not mediated by action of the compounds at CB 1 receptors. Further support for this hypothesis is derived from the finding that selected "agonist-like" compounds did not activate the CB 1 receptor in the [
35 S]GTP␥S assay nor were the in vivo effects of the compounds antagonized by rimonabant. In addition, these compounds produced similar profiles of in vivo effects in CB 1 (Ϫ/Ϫ) and CB 1 (ϩ/ϩ) mice. Together, these results strongly suggest that 3-substituted analogs of rimonabant represent a novel class of cannabinoids that structurally resemble CB 1 receptor antagonists, but produce a profile of activity in mice similar to that of cannabinoid agonists through a non-CB 1 , non-CB 2 mechanism. To date, this novel mechanism has not been identified, but may be the putative CB 3 receptor.
